Human Papillomavirus Protein E6 (E6) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Human Papillomavirus Protein E6 (E6)- Pipeline Review, H2 2019’, provides in depth analysis on Human Papillomavirus Protein E6 (E6) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Women’s Health, Infectious Disease and Gastrointestinal under development targeting Human Papillomavirus Protein E6 (E6).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E6 (E6)

– The report reviews Human Papillomavirus Protein E6 (E6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics and enlists all their major and minor projects

– The report assesses Human Papillomavirus Protein E6 (E6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Human Papillomavirus Protein E6 (E6) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E6 (E6)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E6 (E6) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Abion Inc

AstraZeneca Plc

BioNTech SE

Cellid Co Ltd

Etubics Corp

Genexine Inc

Hookipa Pharma Inc

Immunomic Therapeutics Inc

Innovene

Inovio Pharmaceuticals Inc

Ispin Inc

Papivax LLC

Rottapharm Biotech Srl

Selecta Biosciences Inc

Touchlight Genetics Ltd

Transgene SA

UbiVac LLC

ViciniVax BV

Vir Biotechnology Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Human Papillomavirus Protein E6 (E6) - Overview

Human Papillomavirus Protein E6 (E6) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Human Papillomavirus Protein E6 (E6) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Human Papillomavirus Protein E6 (E6) - Companies Involved in Therapeutics Development

Abion Inc

BioNTech AG

Cancer Research Technology Ltd

Etubics Corp

Genexine Inc

Hookipa Biotech AG

Immunomic Therapeutics Inc

Inovio Pharmaceuticals Inc

MedImmune LLC

Rottapharm Biotech Srl

Selecta Biosciences Inc

Touchlight Genetics Ltd

Transgene SA

Human Papillomavirus Protein E6 (E6) - Drug Profiles

ABN-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Inhibit E6 for HPV Associated Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bizalimogene ralaplasmid + mavilimogene ralaplasmid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BVAC-C - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETBX-041 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GX-188E - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus [serotype 16] vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-3106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ITI-2000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-0457 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit E6 for Human Papillomavirus (HPV) Associated Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Target E6 and E7 for Human Papillomavirus (HPV) Associated Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVX-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SEL-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TA-CIN - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tipapkinogene sovacivec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tricurin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for HPV Associated Cervical Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target E6 and E7 for Human Papillomavirus (HPV) Associated Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vvax-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Human Papillomavirus Protein E6 (E6) - Dormant Products

Human Papillomavirus Protein E6 (E6) - Discontinued Products

Human Papillomavirus Protein E6 (E6) - Product Development Milestones

Featured News & Press Releases

Oct 02, 2018: Major Cancer Journal highlights data from An Inovio-Sponsored trial in which a patient achieved full remission after dosing with DNA immunotherapy and checkpoint inhibitor

Sep 21, 2018: DNA vaccine leads to immune responses in HPV-related head and neck cancer

May 21, 2018: Inovio Opens Phase 2 Trial for VGX-3100 in Third Indication To Treat HPV - The No. 1 Sexually Transmitted Disease

May 15, 2018: New Insights into Hookipa's TheraT Replicating Viral Vector Platform Published in Immunity

Jan 08, 2018: Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase 2

Nov 29, 2017: Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy

Nov 27, 2017: Inovio Pharmaceuticals Provides Update on Cancer Drug Candidate INO-3112

Nov 10, 2017: Inovio Pharmaceuticals Presents data on MEDI0457 at Society for Immunotherapy of Cancer Conference

Sep 19, 2017: Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers

Jun 19, 2017: Genexine Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Therapeutic DNA Vaccine, in Combination With KEYTRUDA, for the Treatment of HPV-Induced Cervical Cancer

Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer

May 10, 2017: Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer

Apr 24, 2017: Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers

Mar 06, 2017: Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech

Nov 14, 2016: Inovios Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Abion Inc, H2 2019

Pipeline by AstraZeneca Plc, H2 2019

Pipeline by BioNTech SE, H2 2019

Pipeline by Cellid Co Ltd, H2 2019

Pipeline by Etubics Corp, H2 2019

Pipeline by Genexine Inc, H2 2019

Pipeline by Hookipa Pharma Inc, H2 2019

Pipeline by Immunomic Therapeutics Inc, H2 2019

Pipeline by Innovene, H2 2019

Pipeline by Inovio Pharmaceuticals Inc, H2 2019

Pipeline by Ispin Inc, H2 2019

Pipeline by Papivax LLC, H2 2019

Pipeline by Rottapharm Biotech Srl, H2 2019

Pipeline by Selecta Biosciences Inc, H2 2019

Pipeline by Touchlight Genetics Ltd, H2 2019

Pipeline by Transgene SA, H2 2019

Pipeline by UbiVac LLC, H2 2019

Pipeline by ViciniVax BV, H2 2019

Pipeline by Vir Biotechnology Inc, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports